Papers
Schvartzman JM, Forsyth G, Walch H, Chatila W, Taglialatela A, Lee BJ, Zhu X, Gershik S, Cimino FV, Santella A, Menghrajani K, Ciccia A, Koche R, Sánchez-Vega F, Zha S, Thompson CB. Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination. Mol Cell. 2023 Jun 7:S1097-2765(23)00382-9. doi: 10.1016/j.molcel.2023.05.026. Online ahead of print. PMID: 37311462
Schvartzman JM, Intlekofer AM. D-2HG comes out of its shell: Metabolic effects on the immune environment. Mol Cell. 2022 Dec 1;82(23):4407-4409. doi: 10.1016/j.molcel.2022.11.005.PMID: 36459984
Wang T, Drill E, Vakiani E, Pak LM, Boerner T, Askan G, Schvartzman JM, Simpson AL, Jarnagin WR, Sigel CS. Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma. Hum Pathol. 2019 Sep;91:19-25. doi: 10.1016/j.humpath.2019.05.002. Epub 2019 May 21. PubMed PMID: 31121195; PubMed Central PMCID: PMC6744317.
Schvartzman JM, Reuter VP, Koche RP, Thompson CB. 2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation.Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12851-12856. doi: 10.1073/pnas.1817662116. Epub 2019 Jun 10. PubMed PMID: 31182575; PubMed Central PMCID: PMC6600935.
Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discov. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877. Epub 2018 Oct 24. PubMed PMID: 30355724; PubMed Central PMCID: PMC6699636.
Schvartzman JM, Thompson CB, Finley LWS. Metabolic regulation of chromatin modifications and gene expression. J Cell Biol. 2018 Jul 2;217(7):2247-2259. doi: 10.1083/jcb.201803061. Epub 2018 May 14. Review. PubMed PMID: 29760106; PubMed Central PMCID: PMC6028552.
Schvartzman JM, Duijf PH, Sotillo R, Coker C, Benezra R. Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. Cancer Cell. 2011 Jun 14;19(6):701-14. doi: 10.1016/j.ccr.2011.04.017. PubMed PMID: 21665145; PubMed Central PMCID: PMC3120099.
Sotillo R, Schvartzman JM, Socci ND, Benezra R. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature.2010 Mar 18;464(7287):436-40. doi: 10.1038/nature08803. Epub 2010 Feb 21. PubMed PMID: 20173739; PubMed Central PMCID: PMC2841716.
Schvartzman JM, Sotillo R, Benezra R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer. 2010 Feb;10(2):102-15. doi: 10.1038/nrc2781. Review. PubMed PMID: 20094045; PubMed Central PMCID: PMC5526619.
Sotillo R, Schvartzman JM, Benezra R. Very CIN-ful: whole chromosome instability promotes tumor suppressor loss of heterozygosity. Cancer Cell. 2009 Dec 8;16(6):451-2. doi: 10.1016/j.ccr.2009.11.014. PubMed PMID: 19962661; PubMed Central PMCID: PMC5513159.
Diaz-Rodríguez E, Sotillo R, Schvartzman JM, Benezra R. Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo.Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16719-24. doi: 10.1073/pnas.0803504105. Epub 2008 Oct 21. PubMed PMID: 18940925; PubMed Central PMCID: PMC2570608.
Schvartzman JM, Schvartzman JB. How do we ask for money? A view of funding for basic research. EMBO Rep. 2008 Mar;9(3):216-20. doi: 10.1038/embor.2008.16. PubMed PMID: 18311169; PubMed Central PMCID: PMC2267380.